UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Effect of Vildagliptin on Hepatic Steatosis

The journal of clinical endocrinology and metabolism, 2015-04, Vol.100 (4), p.1578-1585

2015

Volltextzugriff (PDF)

Insights Into GLP-1 and GIP Actions Emerging From Vildagliptin Mechanism Studies in Man

Frontiers in endocrinology (Lausanne), 2019-11, Vol.10, p.780-780

Foley, James E.

2019

Volltextzugriff (PDF)

Vildagliptin Reduces Glucagon during Hyperglycemia and Sustains Glucagon Counterregulation during Hypoglycemia in Type 1 Diabetes

The journal of clinical endocrinology and metabolism, 2012-10, Vol.97 (10), p.3799-3806

2012

Volltextzugriff (PDF)

Weight neutrality with the DPP-4 inhibitor, vildagliptin: mechanistic basis and clinical experience

Vascular health and risk management, 2010-01, Vol.6 (default), p.541-548

2010

Volltextzugriff (PDF)

Improved glucose regulation in type 2 diabetic patients with DPP-4 inhibitors: focus on alpha and beta cell function and lipid metabolism

Diabetologia, 2016-05, Vol.59 (5), p.907-917

2016

Volltextzugriff (PDF)

Effects of Dipeptidyl Peptidase-4 Inhibition on Gastrointestinal Function, Meal Appearance, and Glucose Metabolism in Type 2 Diabetes

Diabetes (New York, N.Y.), 2007-05, Vol.56 (5), p.1475-1480

2007

Volltextzugriff (PDF)

Effects of the Dipeptidyl Peptidase-IV Inhibitor Vildagliptin on Incretin Hormones, Islet Function, and Postprandial Glycemia in Subjects With Impaired Glucose Tolerance

Diabetes care, 2008, Vol.31 (1), p.30-35

2008

Volltextzugriff (PDF)

Dipeptidyl-Peptidase-IV Inhibition Augments Postprandial Lipid Mobilization and Oxidation in Type 2 Diabetic Patients

The journal of clinical endocrinology and metabolism, 2009-03, Vol.94 (3), p.846-852

2009

Volltextzugriff (PDF)

Dipeptidyl Peptidase-4 Inhibitor Vildagliptin Improves β-Cell Function and Insulin Sensitivity in Subjects With Impaired Fasting Glucose

Diabetes care, 2008, Vol.31 (1), p.108-113

2008

Volltextzugriff (PDF)

Estimation of the Relative Contribution of Postprandial Glucose Exposure to Average Total Glucose Exposure in Subjects with Type 2 Diabetes

International Journal of Endocrinology, 2016-01, Vol.2016 (2016), p.427-430-047

2016

Volltextzugriff (PDF)

Assessing the general safety and tolerability of vildagliptin: value of pooled analyses from a large safety database versus evaluation of individual studies

Vascular health and risk management, 2011-01, Vol.7, p.49-57

2011

Volltextzugriff (PDF)

Effects of vildagliptin on postprandial markers of bone resorption and calcium homeostasis in recently diagnosed, well-controlled type 2 diabetes patients

Journal of diabetes, 2012-06, Vol.4 (2), p.181-185

2012

Volltextzugriff (PDF)

Dipeptidyl Peptidase-4 Inhibition by Vildagliptin and the Effect on Insulin Secretion and Action in Response to Meal Ingestion in Type 2 Diabetes

Diabetes care, 2009, Vol.32 (1), p.14-18

2009

Volltextzugriff (PDF)

Efficacy of vildagliptin versus sulfonylureas as add-on therapy to metformin: comparison of results from randomised controlled and observational studies

Diabetologia, 2014-07, Vol.57 (7), p.1304-1307

2014

Volltextzugriff (PDF)

The effect of dipeptidyl peptidase-4 inhibition on gastric volume, satiation and enteroendocrine secretion in type 2 diabetes: a double-blind, placebo-controlled crossover study

Clinical endocrinology (Oxford), 2008-11, Vol.69 (5), p.737-744

2008

Volltextzugriff (PDF)

Four-Point Preprandial Self-Monitoring of Blood Glucose for the Assessment of Glycemic Control and Variability in Patients with Type 2 Diabetes Treated with Insulin and Vildagliptin

International Journal of Endocrinology, 2015-01, Vol.2015 (2015), p.147-153-118

2015

Volltextzugriff (PDF)

Improved meal-related β-cell function and insulin sensitivity by the dipeptidyl peptidase-IV inhibitor vildagliptin in metformin-treated patients with type 2 diabetes over 1 year

Diabetes care, 2005-08, Vol.28 (8), p.1936-1940

2005

Volltextzugriff (PDF)

Vildagliptin Enhances Islet Responsiveness to Both Hyper- and Hypoglycemia in Patients with Type 2 Diabetes

The journal of clinical endocrinology and metabolism, 2009-04, Vol.94 (4), p.1236-1243

2009

Volltextzugriff (PDF)

DPP-4 inhibitor treatment: β-cell response but not HbA1c reduction is dependent on the duration of diabetes

Vascular health and risk management, 2017-03, Vol.13, p.123-126

2017

Volltextzugriff (PDF)

Insulin Resistance and Insulin Secretory Dysfunction as Precursors of Non-Insulin-Dependent Diabetes Mellitus: Prospective Studies of Pima Indians

The New England journal of medicine, 1993-12, Vol.329 (27), p.1988-1992

1993

Volltextzugriff (PDF)

Comparison of vildagliptin and sitagliptin in patients with type 2 diabetes and severe renal impairment: a randomised clinical trial

Diabetologia, 2015-09, Vol.58 (9), p.2020-2026

2015

Volltextzugriff (PDF)

In Vitro lipolysis is associated with whole‐body lipid oxidation and weight gain in humans

Obesity (Silver Spring, Md.), 2017-01, Vol.25 (1), p.207-214

2017

Volltextzugriff (PDF)

Changes in Prandial Glucagon Levels After a 2-Year Treatment With Vildagliptin or Glimepiride in Patients With Type 2 Diabetes Inadequately Controlled With Metformin Monotherapy

Diabetes care, 2010-04, Vol.33 (4), p.730-732

2010

Volltextzugriff (PDF)

The Dipeptidyl Peptidase IV Inhibitor Vildagliptin Suppresses Endogenous Glucose Production and Enhances Islet Function after Single-Dose Administration in Type 2 Diabetic Patients

The journal of clinical endocrinology and metabolism, 2007-04, Vol.92 (4), p.1249-1255

2007

Volltextzugriff (PDF)

Effect of vildagliptin as add-on therapy to a low-dose metformin

World journal of diabetes, 2010-03, Vol.1 (1), p.19-26

2010

Volltextzugriff (PDF)

1 – 25 von 658

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(598)
Mit Volltextzugriff
(559)

Publikationsform

1 weiteren anzeigen...

Weniger anzeigen...

Sprache

Erscheinungsjahr

n.n

Thema

Science & Technology
(435)
Life Sciences & Biomedicine
(353)
Humans
(252)
Male
(160)
Female
(148)
Biological And Medical Sciences
(113)
Animals
(107)
Middle Aged
(98)
Medical Sciences
(97)
Adult
(78)
Aged
(70)
Physical Sciences
(68)
Endocrinology & Metabolism
(52)
Pharmacology & Pharmacy
(49)
Pharmacology. Drug Treatments
(49)
Cardiovascular System & Cardiology
(46)
Mice
(41)
Rats
(40)
Treatment Outcome
(39)
Diabetes Mellitus, Type 2 - Drug Therapy
(38)

15 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 30 Tagen
(1)
... seit 90 Tagen
(2)

Menü

Weitere Dienste

Einstellungen

Effect of Vildagliptin on Hepatic Steatosis

Insights Into GLP-1 and GIP Actions Emerging From Vildagliptin Mechanism Studies in Man

Vildagliptin Reduces Glucagon during Hyperglycemia and Sustains Glucagon Counterregulation during Hypoglycemia in Type 1 Diabetes

Weight neutrality with the DPP-4 inhibitor, vildagliptin: mechanistic basis and clinical experience

Improved glucose regulation in type 2 diabetic patients with DPP-4 inhibitors: focus on alpha and beta cell function and lipid metabolism

Effects of Dipeptidyl Peptidase-4 Inhibition on Gastrointestinal Function, Meal Appearance, and Glucose Metabolism in Type 2 Diabetes

Effects of the Dipeptidyl Peptidase-IV Inhibitor Vildagliptin on Incretin Hormones, Islet Function, and Postprandial Glycemia in Subjects With Impaired Glucose Tolerance

Dipeptidyl-Peptidase-IV Inhibition Augments Postprandial Lipid Mobilization and Oxidation in Type 2 Diabetic Patients

Dipeptidyl Peptidase-4 Inhibitor Vildagliptin Improves β-Cell Function and Insulin Sensitivity in Subjects With Impaired Fasting Glucose

Estimation of the Relative Contribution of Postprandial Glucose Exposure to Average Total Glucose Exposure in Subjects with Type 2 Diabetes

Assessing the general safety and tolerability of vildagliptin: value of pooled analyses from a large safety database versus evaluation of individual studies

Effects of vildagliptin on postprandial markers of bone resorption and calcium homeostasis in recently diagnosed, well-controlled type 2 diabetes patients

Dipeptidyl Peptidase-4 Inhibition by Vildagliptin and the Effect on Insulin Secretion and Action in Response to Meal Ingestion in Type 2 Diabetes

Efficacy of vildagliptin versus sulfonylureas as add-on therapy to metformin: comparison of results from randomised controlled and observational studies

The effect of dipeptidyl peptidase-4 inhibition on gastric volume, satiation and enteroendocrine secretion in type 2 diabetes: a double-blind, placebo-controlled crossover study

Four-Point Preprandial Self-Monitoring of Blood Glucose for the Assessment of Glycemic Control and Variability in Patients with Type 2 Diabetes Treated with Insulin and Vildagliptin

Improved meal-related β-cell function and insulin sensitivity by the dipeptidyl peptidase-IV inhibitor vildagliptin in metformin-treated patients with type 2 diabetes over 1 year

Vildagliptin Enhances Islet Responsiveness to Both Hyper- and Hypoglycemia in Patients with Type 2 Diabetes

DPP-4 inhibitor treatment: β-cell response but not HbA1c reduction is dependent on the duration of diabetes

Insulin Resistance and Insulin Secretory Dysfunction as Precursors of Non-Insulin-Dependent Diabetes Mellitus: Prospective Studies of Pima Indians

Comparison of vildagliptin and sitagliptin in patients with type 2 diabetes and severe renal impairment: a randomised clinical trial

In Vitro lipolysis is associated with whole‐body lipid oxidation and weight gain in humans

Changes in Prandial Glucagon Levels After a 2-Year Treatment With Vildagliptin or Glimepiride in Patients With Type 2 Diabetes Inadequately Controlled With Metformin Monotherapy

The Dipeptidyl Peptidase IV Inhibitor Vildagliptin Suppresses Endogenous Glucose Production and Enhances Islet Function after Single-Dose Administration in Type 2 Diabetic Patients

Effect of vildagliptin as add-on therapy to a low-dose metformin

Suchergebnisse filtern